Are there clinical trials focused on reversing organ damage caused by AL amyloidosis? This is a really important question, and the short answer is: yes, there is promising research underway.
One of the most exciting developments is a monoclonal antibody called CAEL-101. Unlike most current treatments that focus on stopping Show Full Answer
Are there clinical trials focused on reversing organ damage caused by AL amyloidosis? This is a really important question, and the short answer is: yes, there is promising research underway.
One of the most exciting developments is a monoclonal antibody called CAEL-101. Unlike most current treatments that focus on stopping new amyloid from forming, CAEL-101 is being studied specifically for its potential to actually remove amyloid deposits that have already built up in organs. That's a meaningful distinction — it targets the damage that's already been done. Another emerging treatment that has received FDA orphan drug designation is NXC-201, a type of CAR T-cell therapy. This approach involves reprogramming your own immune cells to recognize and attack the abnormal cells responsible for amyloidosis. Orphan drug status is given to treatments for rare conditions, which helps speed up the research and approval process.
Here's a quick summary of what's being explored:
- CAEL-101 — may help remove existing amyloid deposits from organs
- NXC-201 (CAR T-cell therapy) — uses your own reprogrammed immune cells to fight the disease at its source
Clinical trials can offer access to treatments not yet widely available. Talking with a specialist who focuses on amyloidosis is the best way to find out which trials might be a good fit based on your specific situation and organ involvement.
May 13
Join
Your Privacy Choices
